MorphoSys (ETR:MOR) received a €114.00 ($132.56) price objective from Goldman Sachs Group in a research report issued on Thursday, September 26th, Borsen Zeitung reports. The firm presently has a “neutral” rating on the stock. Goldman Sachs Group’s price objective suggests a potential upside of 16.74% from the company’s previous close.
Several other analysts have also recently commented on the stock. Deutsche Bank set a €133.00 ($154.65) price objective on shares of MorphoSys and gave the company a “buy” rating in a research note on Thursday, August 8th. JPMorgan Chase & Co. set a €130.00 ($151.16) price objective on shares of MorphoSys and gave the company a “buy” rating in a research note on Wednesday, September 11th. HSBC set a €81.00 ($94.19) price objective on shares of MorphoSys and gave the company a “sell” rating in a research note on Friday, August 16th. Royal Bank of Canada set a €130.00 ($151.16) price objective on shares of MorphoSys and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Independent Research set a €117.00 ($136.05) price objective on shares of MorphoSys and gave the company a “neutral” rating in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company’s stock. MorphoSys currently has an average rating of “Hold” and a consensus target price of €119.78 ($139.28).
MorphoSys stock traded up €0.45 ($0.52) during midday trading on Thursday, hitting €97.65 ($113.55). 148,770 shares of the company’s stock were exchanged, compared to its average volume of 153,687. The stock has a market cap of $3.08 billion and a price-to-earnings ratio of -73.92. The firm’s 50 day simple moving average is €104.39 and its 200 day simple moving average is €95.02. The company has a debt-to-equity ratio of 8.61, a quick ratio of 7.40 and a current ratio of 7.62. MorphoSys has a 12-month low of €76.45 ($88.90) and a 12-month high of €114.70 ($133.37).
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Featured Article: Hold Rating
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.